TNF and psoriasis: Real-life data evaluating the risk of severe infections in 11,560 new IB treatments in patients with psoriasis and psoriatic arthritis identified a reduced risk of serious infections in patients treated with anti-IL17 and anti-IL12/23, when compared to the use of anti-TNF in patients without previous exposure to IBs.